For a global law firm of its scale, Orrick stands out for its narrow sector focus and excellence in its chosen areas. Its 25+ offices globally are set on serving clients in four sectors: technology and innovation, decarbonisation & infrastructure modernisation, finance & fintech, and life sciences & healthtech. This sharp focus is mirrored in its London practice, where its venture capital and renewable energy capabilities earned Band 1 and Band 2 rankings from Chambers UK 2025. The London office has also achieved steady revenue growth of 3–5% annually over the past three years, reaching approximately £76 million by the end of 2023.
Orrick’s London Technology Companies Group advises companies and investors at all stages of financings and investments from pre-seed through to strategic exits including IPOs. The team has been ranked no. 1 by Pitchbook in the European venture capital tech market by deal volume for eight years in a row and recognised by Chambers UK for venture capital investment for 16 years in a row. This sustained market leadership has allowed Orrick to cultivate a vast industry network and a comprehensive understanding of market trends, which it continues to actively expand. Orrick’s London Technology Companies Group frequently hosts events to bring the venture capital community together, such as the Investor Speed Networking Event (co-hosted with Innovate Finance) and the Annual London Technology Client Reception. They also provide practical insights for UK startups through the UK Founder Series and market analyses in their proprietary Deal Flow report, now in its fourth year of publication. A further competitive edge of the group lies in the firm’s deep roots in Silicon Valley and the ranks of US-qualified lawyers in London, providing startup clients with seamless access to expertise as they seek to raise money from deep-pocketed US institutional investors in later stages. For example, the team has advised OKYO Pharma Limited, a UK-based biotechnology company focused on developing treatments to inflammatory dry eye diseases, on its Main Market IPO and Nasdaq dual-listing for a total of $2.5 million fundraising, as well as its subsequent Main Market de-listing due to low trading volume.
* Legal 500 (London) ranking
29 offices in 10 countries